Citicoline–liposome/polyurethane composite scaffolds regulate the inflammatory response of microglia to promote nerve regeneration

Lin, Jingjing; Song, Xing-Ying; Yin, Hang; Song, Ning; Wang, Yanchao; Li, Zhen; Luo, Feng; Tan, Hong; He, Xueling; Li, Jiehua

doi:10.1007/s10853-021-06628-0

Cited by 3 publications

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The purified CDP-choline-loaded liposomes were dried under vacuum by using a ThermoScientific™ Savant™ SpeedVac™ (Fisher Scientific Italia, Rodano (MI), Italy) for 12 h. Dried liposomes were dissolved by using cooled methanol (+ 4 °C) and the CDP-choline entrapment efficiency was evaluated by using HPLC apparatus as previously reported by Lin et al with some modification [36] . Samples were analyzed by using a C18 column (4.6 × 100 mm, 3 μm, Gemini-Nx plus C18; Phenomenex, CA, USA) at 25 °C.…”

Section: Drug Entrapment Efficiency and Release Kinetic Of Liposomesmentioning

confidence: 99%

OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline

d'Avanzo,

Paolino,

Barone

et al. 2024

Preprint

View full text Add to dashboard Cite

Cerebrovascular impairment still represents one of the main causes of death worldwide with a mortality rate of 5.5 million per year. Furthermore, the disability of 50% of surviving patients represents a factor with both a high social impact and high costs for long periods of time for national healthcare systems. For these reasons, the efficacious clinical treatment of patients suffering of a brain ischemic stroke is still a medical need. To this aim, a liposome nanomedicine having monosialic ganglioside type 1 (GM1) between its constituent and bearing OX26 (an anti-transferrin receptor antibody) was prepared by entrapping CDP-choline (a neurotrophic drug) (CDP-choline/OX26Lip), characterized and tested in vivo on an ischemic rat model. CDP-choline/OX26Lip were prepared by a freeze and thaw followed by extrusion through polycarbonate filters, thus achieving ~80 nm mean size and a homogeneous size distribution. It was demonstrated that CDP-choline/OX26Lip showed a suitable stability in the presence of human serum. CDP-choline/OX26Lip showed also a suitable pharmacokinetic profile, having 30.0±4.2 % of the administered dose in the blood stream 12 h after its systemic administration. The post-ischemic therapeutic effect of CDP-choline/OX26Lip is better than CDP-choline/Lip, thus showing a significant greater survival rate of re-perfused post-ischemic rats, i.e. 96% and 78% after 8 days, respectively. The treatment with CDP-choline/OX26Lip significantly decreased the peroxidation rate of almost 5-fold compared to CDP-choline/Lip, as expressed in amount of conjugated dienes,i.e. 13.9 ± 1.1 and 3.1 ± 0.8 mmol/mg proteins, respectively. The increased therapeutic effect could be attributed to the improved accumulation of the encapsulated CDP-choline delivered by the OX26-conjugated GM1-liposomes. Therefore, this nanomedicine may represent a suitable strategy for the reassessment of CDP-choline as a line option in the therapeutic treatment of post-ischemic events caused by brain stroke, thus responding to significant clinical needs.

show abstract

Section: Drug Entrapment Efficiency and Release Kinetic Of Liposomesmentioning

confidence: 99%

OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline

d'Avanzo,

Paolino,

Barone

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline

d’Avanzo,

Paolino,

Barone

et al. 2024

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Cerebrovascular impairment represents one of the main causes of death worldwide with a mortality rate of 5.5 million per year. The disability of 50% of surviving patients has high social impacts and costs in long period treatment for national healthcare systems. For these reasons, the efficacious clinical treatment of patients, with brain ischemic stroke, remains a medical need. To this aim, a liposome nanomedicine, with monosialic ganglioside type 1 (GM1), OX26 (an anti-transferrin receptor antibody), and CDP-choline (a neurotrophic drug) (CDP-choline/OX26Lip) was prepared. CDP-choline/OX26Lip were prepared by a freeze and thaw method and then extruded through polycarbonate filters, to have narrow size distributed liposomes of ~80 nm. CDP-choline/OX26Lip were stable in human serum, they had suitable pharmacokinetic properties, and 30.0 ± 4.2% of the injected drug was still present in the blood stream 12 h after its systemic injection. The post-ischemic therapeutic effect of CDP-choline/OX26Lip is higher than CDP-choline/Lip, thus showing a significantly high survival rate of the re-perfused post-ischemic rats, i.e. 96% and 78% after 8 days. The treatment with CDP-choline/OX26Lip significantly decreased the peroxidation rate of ~5-times compared to CDP-choline/Lip; and the resulting conjugated dienes, that was 13.9 ± 1.1 mmol/mg proteins for CDP-choline/Lip and 3.1 ± 0.8 for CDP-choline/OX26Lip. OX26 increased the accumulation of GM1-liposomes in the brain tissues and thus the efficacious of CDP-choline. Therefore, this nanomedicine may represent a strategy for the reassessment of CDP-choline to treat post-ischemic events caused by brain stroke, and respond to a significant clinical need. Graphical abstract

show abstract

Immune-microenvironment modulatory polyurethane-hyaluronic acid hybrid hydrogel scaffolds for diabetic wound treatment

Feng

Xiao

Chen

et al. 2023

Carbohydrate Polymers

View full text Add to dashboard Cite

Citicoline–liposome/polyurethane composite scaffolds regulate the inflammatory response of microglia to promote nerve regeneration

Cited by 3 publications

References 61 publications

OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline

OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline

OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline

Immune-microenvironment modulatory polyurethane-hyaluronic acid hybrid hydrogel scaffolds for diabetic wound treatment

Contact Info

Product

Resources

About